Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Cancer"
DOI: 10.1038/s41416-021-01334-9
Abstract: Background This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression. Methods Eligible adults had aHCC, progression after ≥4 weeks of… read more here.
Keywords: phase; met overexpression; sorafenib pretreated; advanced hepatocellular ... See more keywords